Method Development Strategy and Applications Update for CHIROBIOTIC Chiral Stationary Phases

Abstract

Obtaining enantioselective separations using bonded macrocyclic glycopeptides has increased dramatically over the last several years. The products, trademarked CHIROBIOTIC phases, have advanced based on a host of publications shedding light on the mechanisms of interaction for a variety of diverse chiral analytes. This presentation will cover a brief history of these CSPs development, identify the mechanisms of interaction, and describe the mobile phases that drive those interactions. Details of operating conditions and a proposed method development protocol will be presented with validation statistics. Referenced publications will cover the period from 2004–2008 and will cover both chiral drug assays in the pharmaceutical area and chiral clinical assays utilizing a variety of detection methods. Column testing, storage, and trouble shooting tips have also been included to complete a thorough evaluation of what is known for successful operating conditions.

Keywords:

• Chiral drugs
• Chiral separations
• CHIROBIOTIC phases
• Clinical LC/MS methods
• Enantioseparations

Notes

Of forty racemic switch drugs tested in this study:

The success rate for CHIROBIOTIC phases is ∼ 80%.

The success rate for CYCLOBOND phases is ∼ 40%.

Eight compounds can be separated by both types ∼ (20%).

Resolution range:

CYCLOBOND: 1.5 to 2.8

CHIROBIOTICS: 1.5 to 11.0